TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Mobile Application to Promote Self-management and Improve Outcomes in Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 years and older at screening~2. Currently admitted or discharged from the hospital within the last 14 days with a diagnosis of acute or acute on chronic decompensated HF.~3. Based on one of the EF criteria (LVEF within 12 months of randomization. BNP or NT-proBNP criteria within 30 days prior to randomization):~   * Left ventricular ejection fraction (LVEF) ≤ 40%.~  * LVEF \>40% and BNP \> 175 pg/ml or NT-proBNP \> 700 pg/ml. Thresholds for NT-proBNP and BNP for LVEF \> 40% will be corrected for body mass index (BMI) using a 4% reduction per BMI unit over 25 kg/m2.~4. Have a personal physician for follow-up~5. A smartphone with a compatible Apple or Android operating system installed and able to download and use ManageHF including accepting all permissions~6. A valid email address~7. Fluent in spoken and written English~Exclusion Criteria:~1. Contraindication to recommending a sodium restriction diet~2. Scheduled intervention for primary valvular heart disease will occur during the study period.~3. Cardiac resynchronization therapy (CRT) within 3 months prior to screening or current plan to implant CRT device during the study period.~4. Dialysis~5. Previous cardiac transplantation or implantation of a ventricular assistance device or similar device.~6. Listed status 1, 2 or 3 for heart transplant~7. Implantation of a ventricular assistance device is expected within 3 months after randomization~8. Non-cardiac illness with expected survival of less than 3 months~9. Discharge to a setting other than home~10. Requirement for chronic inotropic therapy (e.g. milrinone, dobutamine)~11. Inability to use Withings devices due to equipment limitations or contraindications~12. Currently pregnant or intend to become pregnant during the study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control Group 'A' (Type: SHAM_COMPARATOR): Standard heart failure educational information.
- Dietary Sodium Intervention 'B' (Type: EXPERIMENTAL): The dietary sodium intervention facilitates lower sodium choices using tailored push notifications.
- Clinical Worsening Intervention 'C' (Type: EXPERIMENTAL): The clinical worsening intervention promotes self-monitoring and self-management and is linked tailored push notifications.
- Dietary Sodium and Clinical Worsening 'D' (Type: EXPERIMENTAL): Full access to all content in the control, dietary sodium, and clinical worsening interventions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Intra-articular and Intra-tendinous Injections for Treatment of Lateral Epicondylitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of lateral epicondylitis based on 2 or more of the following diagnostic criteria: tenderness over the lateral epicondyle; pain with resisted wrist extension; pain with resisted long finger extension.~* Symptoms lasting a minimum of 6 weeks~* Pain score of \>= 3/10 using the Visual Analog Scale (VAS)~* Age \>= 18 years~Exclusion Criteria:~* History of prior elbow surgery~* History elbow fracture within the past year~* Elbow instability on physical examination~* Elbow arthritis on radiographs~* Compressive neuropathy in the affected extremity (i.e.carpal tunnel, cubital tunnel)~* Evidence of cervical myelopathy, radiculopathy or brachial plexopathy~* History of systemic inflammatory condition (i.e. rheumatoid arthritis or systemic lupus erythematosus)~* Allergy to study administered medications (steroid or lidocaine)~* Neoplasm~* Non-English speaking patients~* Inability to comply with study protocols and follow up.~* Pregnant female

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- physical therapy (PT) and rest (Type: None): This group of subjects will be prescribed a physical therapy home exercise program and rest (of the injured elbow).
- PT and intra-tendinous steroid injection (Type: None): This group of subjects will be prescribed a physical therapy home exercise program and will received an intra-tendinous corticosteroid injection into the area of the ECRB origin (of the injured elbow).
- PT and intra-articular steroid injection (Type: None): This group of subjects will be prescribed a physical therapy home exercise program and will received an intra-articular corticosteroid injection into the elbow joint (of the injured elbow).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Averting Complications of Proton Pump Inhibitor Therapy by Effervescent Calcium Magnesium Citrate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must have taken PPI (omeprazole or equivalent ≥ 20 mg/day, ≥ three times per week, for at least 2 months)~* Expected to continue at a similar dosage~* Stage 1 hypertension (with systolic blood pressure \<140 and diastolic \<90)~* controlled diabetes mellitus Type II with HbA1C less than 7%~Exclusion Criteria:~* end-stage renal failure on dialysis~* hypercalcemia~* hypophosphatemia (serum P \< 2.5 mg/dL)~* hypertension stage 2 or higher~* diabetes Type II with HbA1C ≥ 7%~* treatment with adrenocorticosteroids, diuretics, non-steroidal anti-inflammatory agents~* regular dose of magnesium supplements, bisphosphonate, teriparatide, denosumab or selective estrogen receptor modulators.~Inclusion/exclusion of other drugs or conditions will be considered on an individual basis.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 99 Years
- Healthy Volunteers: t

Study Arms:
- EffCaMgCit (Type: EXPERIMENTAL): 19 meq or 380 mg calcium, 10 meq (122 mg) magnesium, and 50 meq total citrate; designed to be added to 6 oz water for 1-2 minutes, to be dissolved/suspended before swallowing. Each sachet of EffCaMgCit will contain 400 units of vitamin D.
- Placebo (Type: PLACEBO_COMPARATOR): Each sachet of Placebo will contain microcrystalline cellulose, but no calcium, magnesium or citrate. Placebo will be added to 6 oz water for 1-2 minutes, to be dissolved/suspended before swallowing. The placebo will contain 400 units of vitamin D.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study to Standardize Allergen Extracts: Determination of Biological Activity in HEP Units

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* 18-65 years old,~* a positive clinical history for inhalant allergy to at least one of the allergens to be tested,~* at least one positive prick test (mean wheal diameter = 3mm) when tested with already standardized extracts of the allergens under investigation.~* a mean wheal size of = 7mm2 obtained in a prick test with histamine dihydrochloride (10mg/ml).~* Written informed consent~Exclusion criteria: -currently suffering from allergy symptoms,~* history of systemic reactions to allergens,~* severe diseases influencing the results of the present study by discretion of the investigator,~* immunotherapy with an allergen preparation known to interfere with the allergens under investigation during the past two years,~* skin lesions in the skin test areas~* pregnancy or nursing,~* treatment with prohibited concomitant medications (antihistamines, corticosteroids, anti-depressants, neuroleptics or specific immunotherapy)~* alcohol or drug abuse,~* impaired in understanding nature, meaning and the scope of the study or are incapable of giving written informed consent,~* Participation in another clinical trial within the last 30 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Eight different allergens will be standardized in this study (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Incidence and Relationship of Positive Preoperative Methicillin Resistant Staphylococcus Aureus (MRSA) Screens and Post-operative Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Pre-surgical out patient at ILH~2. Surgical procedure scheduled at least 2 days before surgery~3. Surgery being done at ILH operating room~4. Provision of signed ICF~Exclusion Criteria:~1. Patient 18 years of age or older who is deemed by the hospital incapable of providing Informed Consent~2. Inability to communicate in the English language

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- No MRSA screening, Group b (Type: NO_INTERVENTION): Standard of care
- MRSA screening, Group a (Type: OTHER): MRSA preoperative screening

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years old~* Symptomatic infection with COVID-19 confirmed by positive RT-PCR SARS-CoV-2 or, failing that, by thorax CT-scan suggesting viral pneumopathy of peripheral predominance in a clinically significant context.~* Diagnosis in the previous two calendar days or, for an asymptomatic patient at the time of virological diagnosis, onset of symptoms in the previous two calendar days.~* Patient having at least one of the following risk factors for developing complications:~  * Age ≥75 years old~ * Age between 60 and 74 years old and presence of at least one comorbidity among the following: obesity (body mass index ≥ 30 kg/m²), arterial hypertension requiring treatment, diabetes mellitus requiring treatment~ * Need for supplemental oxygen to reach a peripheral capillary oxygen saturation of more than 94% (SpO2 \> 94%), or a ratio of partial oxygen pressure to the fraction of inspired oxygen less than or equal to 300 mmHg (PaO2/FiO2 ≤ 300 mmHg).~* Patient affiliated to a social security scheme.~* Written and signed consent of the patient or a relative or emergency inclusion procedure.~Exclusion criteria~* Last RT-PCR negative for SARS-CoV-2~* Peripheral capillary oxygen saturation less than or equal to 94% (SpO2 ≤ 94%) despite oxygen therapy greater than or equal to 3 L/min (\> 3 L/min)~* Organ failure requiring admission to a critical or intensive care unit.~* Comorbidity that is life threatening in the short-term (life expectancy \< 3 months)~* Any reason that makes patient follow-up throughout the study impossible~* Current treatment with hydroxychloroquine~* Absolute contraindication to treatment with hydroxychloroquine (known hypersensitivity, retinopathy, concomitant treatment with risk of ventricular disorders, particularly torsades de pointe, known deficit of glucose-6-phosphate dehydrogenase, porphyria)~* Hypokalaemia \< 3.5 mmol/L~* Corrected QT prolongation (QTc ≥ 440 ms in men and 460 ms in women).~* Child-Pugh's class C liver cirrhosis~* Chronic kidney failure with estimated GFR ≤ 30 ml/min, or ≤ 40 ml/min in patients with concomitant treatment with azithromycin~* Women who are pregnant, breastfeeding, or parturient

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hydroxychloroquine (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Close Kinetic Chain Exercise With Kinesio Taping in the Management of Patellofemoral Pain Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Age between fifteen and thirty-five years,~* Presenting unilateral PFPS with six months of evolution,~* Presenting anterior or retro knee pain that presents itself when undergoing two or more of the following activities:~(squatting, running,kneeling, jumping,climbing stairs,physically active patients, with at least thirty minutes of physical activity at least three times per week.)~Exclusion criteria:~* Patients with previous knee surgeries,~* Chronic pain with more than one year of evolution,~* Pregnancy or suspected pregnancy~* Application of intra-articular steroids in the three months prior to their evaluation~* Patients with meniscal injuries~* Ligament or intra-articular knee structures~* Degenerative diseases such as diabetes~* Rheumatoid arthritis~* Osteoarthritis of the knee, hip or ankle~* History of dislocation or subluxation of patella~* Osgood Schlatter syndrome~* Patellar tendinitis or quadriceps.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Acetaminophen 500mg (Type: ACTIVE_COMPARATOR): The control group will receive treatment with acetaminophen 500mg and physical therapy rehabilitation
- Kinesio taping (Type: EXPERIMENTAL): The experimental treatment group will receive acetaminophen 500mg and physical therapy rehabilitation, plus the application of the technique NUCAP Medical Upper Knee Spider ® Kinesio taping

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Chordate System S020 Acute Migraine Clinical Investigation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with migraine, with or without aura according to International Headache Society (IHS) classification (International Classification of Headache Disorders \[ICHD\]-III beta).~* History of 1 to 6 migraine attacks per month for at least 12 previous months.~* At least 50% of previous migraine attacks had moderate or severe pain intensity.~* History of at least 48 hours of freedom from headache between migraine attacks.~* The majority of the previous untreated migraine attacks lasted at least 8 hours.~* Migraine onset before the age of 50 years.~Exclusion Criteria:~* History (within one year prior to inclusion into this clinical investigation) of 15 or more headache days per month (i.e. headaches of any kind).~* More than 6 days per month with non-migraine headaches (within one year prior to inclusion into this clinical investigation).~* Unable to distinguish between migraine headaches and other headache types at the onset of a migraine attack.~* Treatment with Botox in the head/neck area within 6 months of the screening visit, or between the screening and treatment visit.~* Previously treated with an implantable stimulator or any implantable devices in the head and/or neck.~* Pronounced anterior septal nasal deviation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Chordate System S020 in treatment mode (Type: EXPERIMENTAL): None
- Chordate System S020 in placebo mode (Type: SHAM_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Efficacy in Relief of Dyspnea by HVNI: Evaluation of New Device Equivalence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult inpatients (18 years of age and older)~* Demonstrated severe dyspnea at baseline (Borg Rated Perceived Dyspnea \[RPD\] (scale 0-10) of 3 or higher)~* Severe baseline hypercarbia/hypercapnia of 55 mmHg or higher as measured by TcPCo2 or arterial or venous blood gas~Exclusion Criteria:~* Patient has unstable cardiovascular condition~* Significant unilateral or bilateral nasal occlusion~* Inability to provide informed consent~* Pregnancy~* Known contraindication to perform steps of the protocol~* Absence of spontaneous respiration or known contraindication to HVNI~* Inability to use HVNI therapy~* Agitation or uncooperativeness~* Determined by the clinician to be sufficiently unstable or unsuitable for this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Conventional HVNI First, Then New HVNI Second (Randomized) (Type: EXPERIMENTAL): The purpose of this intervention is to evaluate the efficacy of the conventional HVNI device design (Precision Flow) to provide targeted relief of dyspnea. The purpose of this intervention is to evaluate the efficacy of a new HVNI device design (V2.0) to provide targeted relief of dyspnea.
- New HVNI First, Then Conventional HVNI Second (Randomized) (Type: EXPERIMENTAL): The purpose of this intervention is to evaluate the efficacy of the conventional HVNI device design (Precision Flow) to provide targeted relief of dyspnea. The purpose of this intervention is to evaluate the efficacy of a new HVNI device design (V2.0) to provide targeted relief of dyspnea.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: MiMi: A Randomized Trial of Mifepristone and Misoprostol for Treatment of Early Pregnancy Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>18yrs, able to read and write English~* Intrauterine gestations with anembryonic sac between 10 and 45mm or~* 10-15mm sac with no growth in three days or other radiologic signs of abnormal pregnancy such as irregular sac or debris within the gestational sac~* An embryonic pole \<30mm with no cardiac activity~Exclusion Criteria:~* Intrauterine gestations with CRL \<5mm or \>30mm without cardiac activity~* Incomplete abortion as defined as open cervix and large amount of cramping/bleeding~* Hemodynamic instability and/or heavy vaginal bleeding~* Hemoglobin less than or equal to 8~* Inability to follow-up (ie, lack of transportation or access to telephone)~* Bleeding disorder or taking anticoagulants~* Prior medical or surgical treatment of the current pregnancy~* Obvious Infection~* Active Lactation~* Allergy to mifepristone or misoprostol~* Chronic corticosteroid use~* Severe gastrointestinal disease (e.g inflammatory bowel disease, severe gastritis)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Misoprostol and placebo (Type: ACTIVE_COMPARATOR): Women in this arm receive placebo and misoprostol 800 mcg buccally
- Mifepristone and misoprostol (Type: EXPERIMENTAL): Womwn in this group receive mifepristone 200 mg orally and misoprostol 800 mcg buccally

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Radiotherapy Alone Versus Concurrent Chemoradiation in Low Risk NK/T-cell Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age range 18-75 years old~* Histological confirmed, previously untreated stage IE nasal NK/T cell lymphoma without following risk factors including local invasion, B symptoms and high LDH level~* ECOG performance status 0-1~* Life expectancy of more than 3 months~* Adequate bone marrow and organ functions~Exclusion Criteria:~* non-nasal NK/T-cell lymphoma~* Prior exposure of methotrexate~* With third space effusion~* Pregnant or lactating women~* Serious uncontrolled diseases and intercurrent infection~* History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Radiotherapy alone (Type: ACTIVE_COMPARATOR): Radiotherapy alone Technique: IMRT Total Dose: 50 Gy Per fraction: 2 Gy
- Concurrent chemoradiation (Type: EXPERIMENTAL): Concurrent chemoradiation~Chemotherapy:~Methotrexate 40 mg/m2 weekly X 5 Radiotherapy Technique: IMRT Total dose: 50 Gy Per Fraction: 2 Gy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility